A new report from No Patient Left Behind (NPLB) argues that drug value assessments used by countries such as Canada and Germany systematically undervalue innovative medicines—citing gaps as large as 90% in some analyses. The report frames HTA methods and willingness-to-pay thresholds as outdated and potentially misleading for U.S. policy discussions. NPLB contends that these assessment approaches underestimate benefits not only to patients, but also to families and society, including downstream productivity effects like faster return to work and fewer disability-related costs. The report also highlights how HTA processes can ignore administration and access frictions, such as travel and adherence impacts, which NPLB says distort real-world value. The argument is positioned against proposed U.S. policy directions including potential Most Favored Nations-style pricing adjustments, with NPLB casting the broader system as a driver of innovation rather than a broken market.